Bill Feng

Since joining Kirkland & Ellis, Bill has been involved in the following:

• Super Hi International Holding Ltd. (HKSE: 9658; NASDAQ: HDL) on its initial public offering on the Nasdaq Global Market, making it the first high-profile company to list first in Hong Kong and then in the United States in recent years. This transaction was named “Best IPO – APAC & Hong Kong SAR” and “Most Innovative Deal - Hong Kong SAR” by FinanceAsia Achievement Awards 2024
• ZX Inc. (HKSE: 9890), a leading online game products publisher in China, on its global offering and listing on the Hong Kong Exchanges and Clearing Limited on September 28, 2023
• Super Hi International Holdings Ltd. (HKSE: 9658) on its listing by way of introduction on the Main Board of the Stock Exchange of Hong Kong Limited on December 30, 2022, which constituted a spin-off of Super Hi from the hotpot giant Haidilao International Holding Ltd. (HKSE: 6862) and its separate listing on the Stock Exchange. Super Hi is a leading international Chinese restaurant brand. Morgan Stanley Asia Limited and Huatai Financial Holdings (Hong Kong) Limited were the joint sponsors
• Yunkang Group Limited (HKSE: 2325), a leading medical operation service provider in China that offers a full suite of diagnostic testing services for medical institutions, on its approximately US$140 million global offering and listing on The Stock Exchange of Hong Kong Limited 
• Jiangsu Recbio Technology Co., Ltd. (HKSE: 2179), a vaccine company dedicated to the research, development and commercialization of subunit vaccines, on its global offering and listing of H-shares on the Hong Kong Exchanges and Clearing Limited on March 31, 2022 ‒ the first HPV vaccine stock in Hong Kong 
• The joint sponsors and underwriters on the US$400 million global offering and listing of Keymed Biosciences Inc. (HKSE: 2162), a biotechnology company focuses on the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas, on The Stock Exchange of Hong Kong Limited on July 8, 2021
• Suzhou Basecare Medical Corporate Limited (HKSE:2170), an innovative platform of genetic testing solutions for assisted reproduction in China, in its $233 million global offering of H-shares and listing on the Hong Kong Exchanges and Clearing Limited
• MicroPort CardioFlow Medtech Corporation (HKSE: 2160) in connection with its US$322 million initial public offering and listing on the Main Board of HKEx. The listing is a spin-off from Hong Kong-listed MicroPort Scientific Corporation. MicroPort CardioFlow is a medical device company in China focusing on the research, development, and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases

Prior to joining Kirkland & Ellis, Bill has been involved in the following:

Life Sciences

• MicroPort CardioFlow MedTech Corporation (HKSE: 2160), in connection with its HK$2.35 billion (US$288.1 million) initial public offering on the Main Board of the Stock Exchange of Hong Kong. MicroPort CardioFlow is a subsidiary of MicroPort Scientific Corporation (HKSE: 853), which is a medical device company focusing on the research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases
• Suzhou Basecare Medical Corporation Limited (HKSE: 2170) in connection with its HK$1.68 billion (US$216.0 million) initial public offering on the Main Board of the Stock Exchange of Hong Kong. Suzhou Basecare is an innovative platform of genetic testing solutions for assisted reproduction in China
• Ocumension Therapeutics (HKSE: 1477), in connection with its HK$1.42 billion (US$182.5 million) initial public offering on the Main Board of the Stock Exchange of Hong Kong. Ocumension Therapeutics, which started its business in 2017, is an ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first or best-in-class ophthalmic therapies
  Kangji Medical Holdings Limited (HKSE:9997), in connection with its US$404 million (HK$3.13 billion) initial public offering on the Main Board of the Stock Exchange of Hong Kong. Established in 2004,
• Kangji Medical is the largest domestic minimally invasive surgical instruments and accessories platform in China
• Ascletis Pharma Inc. (HKSE:1672) in connection with its US$457 million initial public offering listed on the Main Board of the Stock Exchange of Hong Kong. Ascletis Pharma Inc. is a fully integrated anti-viral platform focusing on developing and commercializing innovative, best-in-class drugs against HCV, HIV and HBV. This is also the first biotech IPO listing under the HKEx’s new listing regime for emerging and innovative sector
• CCB International Capital Limited and Guosen Securities (HK) Capital Company Limited as joint sponsors and underwriters in connection with Immunotech Biopharm Ltd (HKSE: 6978) ’s initial public offering on the Main Board of the Stock Exchange of Hong Kong

Other Equity Capital Markets

• Yum China Holdings, Inc. (HKSE:9987, NYSE:YUMC) in connection with its secondary listing on the Main Board of The Stock Exchange of Hong Kong. The offering raised net proceeds of approximately HK$17 billion (US$2.2 billion). Yum China is the largest restaurant company in China with flagship brands including KFC and Pizza Hut, as well as emerging brands such as Little Sheep, Huang Ji Huang, COFFii & JOY, East Dawning, Taco Bell, and Lavazza
• Haidilao International Holding Ltd (HKSE: 6862) in connection with its US$964 million initial public offering listed on the Stock Exchange of Hong Kong Main Board. Haidilao International Holding Ltd. is a globally leading and fast-growing Chinese cuisine restaurant brand focusing on hot pot cuisine
• Joy Spreader Interactive Technology. Ltd (HKSE: 6988) in connection with its initial public offering on the Main Board of The Stock Exchange of Hong Kong. The offering raised net proceeds of HK$1.56 billion (approximately US$200 million). Joy Spreader is a leading performance-based we-media marketing service providers in China
• The joint sponsors and underwriters in connection with the HK$975 million (US$125.74 million) IPO on the Main Board of HKEx of Strawbear Entertainment Group (HKSE: 2125)
• Shandong Gold Mining Co., Ltd., A-shares listed company, in its global offering and listing of H-Shares on the Main Board of the Hong Kong Stock Exchange.
• ABCI Capital Limited and China Securities (International) Corporate Finance Company Limited as joint sponsors and underwriters in connection with Bank of Jiujiang Co., Ltd’s global offering and listing of H-Shares on the Main Board of the Stock Exchange of Hong Kong
• China International Capital Corporation Hong Kong Securities Limited, China Merchants Securities (HK) Co., Limited, CCB International Capital Limited and ABCI Capital Limited as joint sponsors and underwriters in connection with Guangzhou Rural Commercial Bank’s initial public offering and listing of H-Shares on the Main Board of the Stock Exchange of Hong Kong.